Pedro is an established, highly-networked and seasoned life-sciences entrepreneur, with over 25-years track record in the biotechnology and healthcare industry.

A graduate from Kings College London he carried out research at Massachusetts Institute of Technology (MIT), the Technical University of Denmark (DTU), and Técnico Lisbon (IST); He further took a 12-months Masters Programme in Management at the University of Texas, Austin. He Founded in 1996 and sold in 2018 the Biotecnol Group of companies, RDN (biopharmaceutical products CDMO company sold to the Iberfar Group) and Biotecnol Limited (a pioneering immuno-oncology company, Sold to Chiome, Inc). Pedro was a Board Member of Vida Rhein SA, part of the Rhein Biotech NV group, developing hepatitis vaccines (sold to Dynavax, Inc) and Board Member of 4Tune Engineering, a Portuguese leading data-analytics and risk-analysis company (sold to Valgenesis, Inc). With a deal flow of over €250M in  financing and transactions, including fund-raising, deal-making, M&A, cross-border. Pedro brings a wealth of experience from an entrepreneurial and leadership perspective across the various components of a biotech company value-chain.
Pedro has collected over the years numerous awards for his pioneering achievements in bioentrepreneurship.

Patrick trained as a Gastroenterologist, and UK MRC Research Fellow in Nutrition and Metabolism.  He has over 35 years of experience in clinical development for  large pharma and small biotech, in regulated markets like  US, Europe, Japan US. He served as Chief Medical Officer at BAI (AI Discovery) and held Chief Medical Officer and R&D Senior management positions at Glenmark Pharma, AstraZeneca, and Eli  Lilly, located in Stockholm, Osaka, Goteborg, Frankfurt, Indianapolis, and London. Patrick was responsible for multiple projects and organisations from Drug Discovery through Development, Regulatory interactions and Approvals, to Market access/Pricing. Therapy focus includes Neurodegeneration, Immuno-oncology, Inflammation, Osteoporosis, Asthma, Insulin analogs, Delivery devices, GLP1 and PPAR inhibitors.

Jens is currently the CEO of the BII Institute, DK; Jens is also a professor at the Chalmers University of Technology and an adjunct professor at DTU and Copenhagen University, with a vast amount of life-science research experience. He is an internationally known key opinion leader in quantitative synthetic and systems biology who has published more than 850 scientific articles that have been cited more than 110,000 times and with a current H-index of 155. He has received numerous awards, including the Novozymes Prize, the ENI Prize, the Eric and Sheila Samson Prime Ministers Prize for Innovation in Alternative Fuels for Transportation, Nature Award for Mentoring, the Emil Chr. Hansen Gold Medal, and the Gold Medal from the Royal Swedish Academy of Engineering Sciences. In 2019 he was honored as Knight, Ridder af Dannebrog (Order of Dannebrog), by Her Majesty The Queen of Denmark, for his meritorious service and contribution to science.

Jens Nielsen has been elected into several academies, including the Royal Swedish Academy of Sciences, the Royal Danish Academy of Science and Letters, the National Academy of Sciences (USA), the National Academy of Engineering (USA),the National Academy of Medicine (USA) and the Chinese Academy of Engineering. Jens Nielsen has several years of entrepreneurial expertise as the founder of biotech companies such as Fluxome A/S, MycoTeQ A/S, MetaboGen AB, Melt&Marble AB, Elypta AB

Rui brings extensive experience in synthetic biology and metabolic engineering projects, from inception and up to industrial stages, across the value chain of development. In addition, Rui has a highly-multidisciplinary background in a variety of fields such as bioprocessing, precision fermentation, downstream processing, and mathematical modelling.  His Ph.D. and postdoctoral studies focused on different aspects of using yeast as a cell factory for producing of valuable biochemicals via rational design and during this time he has gathered technical expertise in genome engineering, fermentation and metabolic modeling. As a researcher he has worked at University of Minho (Portugal) and at Chalmers University of Technology.

Nuno has over 22-years of business experience in Investment Banking. Nuno worked at Banco Santander (Madrid), Dresdner Kleinwort (London), and Banco Espirito Santo Investment (Lisboa). Nuno was responsible for the execution of several innovative and complex transactions across a full range of financial solutions, and products, both on the asset and liability side of Balance Sheets, in various roles from Senior Relationship Manager, Capital Markets Sales, to Equity and Fixed Income Derivatives Trader.

Ruth is a Chartered Management Accountant with extensive professional experience having worked for several large international corporations during her career. She was employed as a sponsored university student with British Gas Plc, before moving on to Reuters in their Italy and London office in various finance roles across the company. She has since worked for Readers Digest in Lisbon and more recently for a number of smaller businesses and startups providing analytical and strategic support to the Board.

Hao is a leading Computational Biology expert, with over  20 years of experience in the fields of genomics, bioinformatics, metabolic engineering, and systems biology. During his career he has made significant contributions to these scientific domains, underpinned by his profound expertise in computational techniques and biological data analysis. Hao has consistently been at the forefront of state-of-the-art computational methods to solve complex biological problems. Hao works in uncovering deeper insights of disease-health mechanisms, through integrative analysis of omics data and metabolic models from both humans and model organisms, by leveraging machine learning and artificial intelligence. Most notably he was involved in the Human-GEM project, a significant breakthrough in the field of genome-scale metabolic models for the study of human metabolism. Human-GEM is an evolving resource bridging the gap between laboratory findings and clinical applications. The project demonstrated its utility in identifying potential biomarkers for the early diagnosis of Alzheimer’s disease.

A highly critical thinker, Leo is an experienced external advisor the Chrysea, brings extensive, experience in the commercialization of high-value branded ingredients, product pricing, profitability, sales forecasting, competitor analysis, marketing strategy, profit maximization. Leo has over 35-years of successful track record in consumer product companies and respective brands, having had senior leadership positions  at Kyowa Hakko Bio, USA (CEO), Lycored, Inc, Buckton Scott Nutrition, MW International, Inc, Hoffmann La-Roche, Inc.

Experienced Senior Business Manager, Business Development professional and Project Management leader with a Scientific Academic background with over 20 years’ experience in Renewable Energy and Biotechnology Life-Science Businesses, namely in Industrial scale-up processes. Played pivotal roles in companies such as Enersis Group, and Infraventus Group. Successfully developed a greenfield Biofuel production Plant Project (Biodiesel 25.000 tpa), under Enersis/Infraventus Group in Portugal, acquired by GALP Energia Corporation. Led the implementation of a Wave Energy Demonstration Project in Peniche, Portugal, development Wind Farm and Solar Farm projects in Portugal, Scandinavia, the Balkan Region and Panamá.

Experience in Biotechnology Innovation development, Product Development and Start-ups, Renewable Energy Greenfield project development of Wind and Solar Farm projects, as well as Wave Energy and Biofuels projects. Led the development of technology and IP positions, with over 40 patents granted in several regions in the world. Directed biotechnology start-up’s projects from bench scale to industrial pilot demonstration and market introduction, namely 73100, and 3 subsidiaries, Pharma73, ExtremoChem (acquired by Hovione Farmacêutica, and Aknout Cosmetics, with new cosmetic products developed and introduced for commercialization in EU and China markets.